Edition:
United States

Chiasma Inc (CXS.F)

CXS.F on Frankfurt Stock Exchange

1.58EUR
1:07pm EDT
Change (% chg)

€0.01 (+0.96%)
Prev Close
€1.56
Open
€1.56
Day's High
€1.58
Day's Low
€1.56
Volume
0
Avg. Vol
25
52-wk High
€3.01
52-wk Low
€1.03

Latest Key Developments (Source: Significant Developments)

Chiasma Q2 loss per share $0.28
Thursday, 10 Aug 2017 04:01pm EDT 

Aug 10 (Reuters) - Chiasma Inc :Chiasma reports second quarter 2017 results.Q2 loss per share $0.28.Chiasma Inc - expect to have a cash and investment balance of at least $60 million at end of 2017.  Full Article

Chiasma reached deal with FDA on late-stage trial of its acromegaly drug
Thursday, 10 Aug 2017 04:00pm EDT 

Aug 10 (Reuters) - Chiasma Inc :Chiasma reaches agreement with FDA under special protocol assessment for a new phase 3 clinical trial of octreotide capsules in acromegaly.Chiasma reaches agreement with fda under special protocol assessment for a new phase 3 clinical trial of octreotide capsules in acromegaly.Chiasma Inc - ‍plans to initiate enrollment in new phase 3 clinical trial - optimal - during second half of 2017​.Chiasma Inc - ‍anticipates release of top-line data from new optimal trial by end of 2019​.Says "‍based on our current plans, we expect to have a cash and investment balance of at least $60 million at end of 2017"​.  Full Article

Chiasma reports Q1 loss per share $0.29
Friday, 5 May 2017 08:01am EDT 

May 5 (Reuters) - Chiasma Inc : :Chiasma reports first quarter 2017 results.Q1 loss per share $0.29.Chiasma Inc - following receipt of crl for octreotide capsules NDA, company participated in an end of review meeting with FDA.Chiasma Inc - FDA "reiterated its strong preference" for a randomized, double-blind and controlled trial for octreotide capsules.Chiasma Inc - for octreotide capsules, FDA suggested that some of its concerns could potentially be addressed through placebo-controlled study design.Chiasma Inc - FDA advised in CRL that, during a site inspection, certain deficiencies were conveyed to representative of one of Chiasma's suppliers.Chiasma Inc - in December 2016, supplier informed chiasma that it had received its establishment inspection report from FDA.Chiasma Inc - expects its existing cash, cash equivalents and marketable securities to fund operations beyond 2018.  Full Article

Chiasma Q4 loss per share $0.32
Thursday, 16 Mar 2017 04:05pm EDT 

Chiasma Inc : Chiasma reports fourth quarter and year end 2016 results . Q4 loss per share $0.32 .Chiasma Inc - for quarter ended december 31, 2016, net loss attributable to common stockholders was $7.9 million, or $0.32 per basic share..  Full Article

Chiasma names Mark J. Fitzpatrick as CEO
Friday, 30 Sep 2016 04:15pm EDT 

Chiasma Inc : Chiasma names Mark J. Fitzpatrick chief executive officer . Says CEO Mark Leuchtenberger resigned .Fitzpatrick currently serves as Chiasma's chief financial officer.  Full Article

Chiasma adopts a retention plan to provide cash retention payments to all remaining employees
Tuesday, 16 Aug 2016 09:59am EDT 

Chiasma Inc : Adopted a retention plan, effective immediately to provide cash retention payments to all remaining employees of co- sec filing . Retention payments are expected to be made in January 2017 Source: (http://bit.ly/2b1crqL) Further company coverage: [CHMA.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Chiasma announces workforce reduction
Tuesday, 16 Aug 2016 09:00am EDT 

Chiasma Inc : Chiasma announces workforce reduction . Continues to enroll patients in its mpowered phase 3 trial . Further reducing its workforce by approximately 44% . Will incur aggregate charges related to headcount reduction of about $0.8 million to $1.0 million for one-time severance and related costs in Q3 . Company expects to realize more than $7.0 million in annualized payroll and related expense savings as a result of restructuring actions . Chiasma Inc says expects to realize more than $7.0 million in annualized payroll and related expense savings as a result of these combined actions .Charges related to headcount reduction expected to result in cash expenditures that will be substantially complete by end of Q1 of 2017.  Full Article

Chiasma records restructuring charge of about $6.5 mln in Q2
Wednesday, 10 Aug 2016 04:02pm EDT 

Chiasma Inc : Chiasma provides corporate update and reports second quarter 2016 results . Recorded a restructuring charge of approximately $6.5 million for quarter ended June 30, 2016 . Chiasma Inc qtrly basic loss per share $1.10 .Approximately $1.8 million of charge was attributable to restructuring plan that was announced in June 2016.  Full Article

Chiasma Inc terminates employment of CCO Anand Varadan
Tuesday, 14 Jun 2016 09:18am EDT 

Chiasma Inc :Terminated employment of Anand Varadan, company's chief commercial officer, effective as of June 17, 2016 - sec filing.  Full Article

Chiasma Q1 loss per share $0.71
Wednesday, 11 May 2016 04:01pm EDT 

Chiasma Inc : Currently revisiting all areas of investment and resources in light of recent receipt of CRL . Revisiting resources to potentially enable an overall reduction of its 2016 expenses and an extension of its cash runway beyond mid-2017 . Qtrly loss per share $0.71 .Chiasma reports first quarter 2016 results.  Full Article

BRIEF-Chiasma reached deal with FDA on late-stage trial of its acromegaly drug

* Chiasma reaches agreement with FDA under special protocol assessment for a new phase 3 clinical trial of octreotide capsules in acromegaly